The primary objective of this study is to conduct a systematic literature review, following the PRISMA guidelines, to evaluate the efficacy of bevacizumab in controlling tumor volume and preserving hearing function in patients with VS and NF2. The gene discussed is NF2; the disease is neoplasm.